{"id":"switch-to-bupropion","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Insomnia"},{"rate":"17-24%","effect":"Dry mouth"},{"rate":"13-18%","effect":"Nausea"},{"rate":"22-26%","effect":"Headache"},{"rate":"6-11%","effect":"Dizziness"},{"rate":"0.4%","effect":"Seizures"},{"rate":null,"effect":"Increased blood pressure"},{"rate":"7-11%","effect":"Tremor"}]},"_chembl":{"chemblId":"CHEMBL1201735","moleculeType":"Small molecule","molecularWeight":"320.66"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bupropion blocks the reuptake transporters for norepinephrine and dopamine at the presynaptic neuron, leading to increased concentrations of these neurotransmitters in the synaptic cleft. Unlike selective serotonin reuptake inhibitors (SSRIs), bupropion has minimal effects on serotonin reuptake. This mechanism is thought to improve mood, motivation, and energy levels, and may also reduce appetite and support smoking cessation.","oneSentence":"Bupropion is an atypical antidepressant that inhibits the reuptake of norepinephrine and dopamine, increasing their availability in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:23.626Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Seasonal affective disorder"},{"name":"Smoking cessation (as Zyban/Wellbutrin SR)"},{"name":"ADHD (off-label use)"}]},"trialDetails":[{"nctId":"NCT05205811","phase":"PHASE3","title":"The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette","status":"COMPLETED","sponsor":"Rose Research Center, LLC","startDate":"2021-12-14","conditions":"Smoking Cessation","enrollment":180},{"nctId":"NCT05603104","phase":"PHASE3","title":"Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-04-27","conditions":"Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression","enrollment":1254},{"nctId":"NCT04490057","phase":"PHASE4","title":"A Smart Approach to Treating Tobacco Use Disorder in Persons Living With HIV","status":"COMPLETED","sponsor":"Yale University","startDate":"2020-07-27","conditions":"Tobacco Use Cessation","enrollment":323},{"nctId":"NCT04604509","phase":"PHASE4","title":"Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-08-04","conditions":"Cigarette Smoking-Related Carcinoma","enrollment":2010},{"nctId":"NCT05973786","phase":"PHASE3","title":"The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-02-11","conditions":"Bipolar Depression","enrollment":418},{"nctId":"NCT05273996","phase":"PHASE4","title":"Predictors of Cognitive Outcomes in Geriatric Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"David Steffens","startDate":"2021-09-28","conditions":"Major Depressive Disorder, Neuroticism, Cognitive Change","enrollment":75},{"nctId":"NCT05531591","phase":"PHASE4","title":"RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2019-08-01","conditions":"Depression, Dementia, Mild Cognitive Impairment","enrollment":87},{"nctId":"NCT02960763","phase":"PHASE4","title":"Optimizing Outcomes of Treatment-Resistant Depression in Older Adults","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-02-24","conditions":"Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression","enrollment":742},{"nctId":"NCT03431831","phase":"PHASE4","title":"Assessment of and Treatment Applied to Food Addiction in a Rural Healthy Behaviors Clinic","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2017-07-01","conditions":"Obesity","enrollment":86},{"nctId":"NCT04478526","phase":"NA","title":"Efficacy of Online CBT for GAD Compared to Pharmaceutical Interventions","status":"COMPLETED","sponsor":"Dr. Nazanin Alavi","startDate":"2020-04-29","conditions":"Generalized Anxiety Disorder","enrollment":115},{"nctId":"NCT04388319","phase":"PHASE3","title":"Zonisamide/Bupropion Effects on Switching to Electronic Cigarettes","status":"COMPLETED","sponsor":"Rose Research Center, LLC","startDate":"2020-05-27","conditions":"Smoking Cessation","enrollment":26},{"nctId":"NCT02501265","phase":"PHASE2","title":"Adaptive Pharmacotherapy for Smoking Cessation","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-06-06","conditions":"Nicotine Dependence","enrollment":188},{"nctId":"NCT00057551","phase":"PHASE4","title":"Research Evaluating the Value of Augmenting Medication With Psychotherapy","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2003-04","conditions":"Depression, Depressive Disorder","enrollment":491},{"nctId":"NCT01032018","phase":"PHASE1, PHASE2","title":"Comparison of Depression Interventions After Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Columbia University","startDate":"2010-01","conditions":"Acute Coronary Syndrome, Depression","enrollment":150},{"nctId":"NCT00616915","phase":"PHASE1","title":"Does Sleep Quality Change After Switch From Wellbutrin SR to Wellbutrin XL in Patients With Major Depressive Disorder?","status":"COMPLETED","sponsor":"Queen's University","startDate":"2007-01","conditions":"Mood Disorder","enrollment":20},{"nctId":"NCT01764867","phase":"PHASE4","title":"Algorithm Guided Treatment Strategies for Major Depressive Disorder","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2012-06","conditions":"Major Depressive Disorder","enrollment":1080}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Wellbutrin"],"phase":"marketed","status":"active","brandName":"Switch to bupropion","genericName":"Switch to bupropion","companyName":"Centre for Addiction and Mental Health","companyId":"centre-for-addiction-and-mental-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bupropion is a small molecule that inhibits the sodium-dependent dopamine transporter, a mechanism that is associated with its effects. It has been studied as a treatment for conditions including cigarette smoking-related carcinoma, major depressive disorder, and stress, among others.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}